Cue Biopharma (CUE) EBT Margin (2018 - 2025)
Cue Biopharma (CUE) posted EBT Margin of 20.65% for Q4 2025, up 105.43% sequentially from 380.69% in Q3 2025, and up 60352.0% YoY from N/an in Q4 2024.
Cue Biopharma (CUE) EBT Margin (2018 - 2025) Analysis & Trends
Cue Biopharma has reported EBT Margin for 8 years, with the latest figure at 20.65% in Q4 2025.
- Quarterly EBT Margin rose 60352.0% year-over-year to 20.65% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 246.21% (up 32774.0% YoY) and the FY2025 annual result came in at 100.27%, up 39800.0% from the prior year.
- EBT Margin advanced to 20.65% in Q4 2025 per CUE's latest filing, from 380.69% in the prior quarter.
- Over five years, EBT Margin peaked at 20.65% in Q4 2025 and troughed at 51138.46% in Q2 2022.
- A 5-year average of 4906.31% and a median of 660.05% in 2021 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2023: EBT Margin tumbled 5076230 bps in 2022, then surged 5015011 bps in 2023.
- Over 5 years, EBT Margin stood at 95.62% in 2021, then tumbled by 10345 bps to 9988.08% in 2022, then soared by 93 bps to 722.9% in 2023, then increased by 19 bps to 582.87% in 2024, then surged by 104 bps to 20.65% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 20.65%, 380.69%, and 492.96% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | -1,111.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 20.65% |
| Sep 30, 2025 | -380.69% |
| Jun 30, 2025 | -492.96% |
| Mar 31, 2025 | -3,850.12% |
| Dec 31, 2024 | -582.87% |
| Sep 30, 2024 | -288.76% |
| Jun 30, 2024 | -589.50% |
| Mar 31, 2024 | -1,095.75% |
| Dec 31, 2023 | -722.90% |
| Sep 30, 2023 | -577.52% |
| Jun 30, 2023 | -988.35% |
| Mar 31, 2023 | -7,331.55% |
| Dec 31, 2022 | -9,988.08% |
| Sep 30, 2022 | -16,404.41% |
| Jun 30, 2022 | -51,138.46% |
| Mar 31, 2022 | -1,433.30% |
| Dec 31, 2021 | -95.62% |
| Sep 30, 2021 | -597.20% |
| Jun 30, 2021 | -376.16% |
| Mar 31, 2021 | -1,212.56% |